Vincerx Pharma, Inc.
VINCW
NASDAQ Global Select1.61
USD
-0.42
- -
CIK
0001796129
Return %
Stock
S&P500
1Y
- -
18.99
3Y
- -
64.75
5Y
- -
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Hans-Georg Lerchen
- Full Time Employees
- 42
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 260 Sheridan Avenue Palo Alto CA United States of America 94306
- IPO Date
- May 21, 2020
- CIK
- 0001796129
- Website
- vincerx.com
- Similar Companies
- Business
- Vincerx Pharma, Inc. was a clinical-stage biopharmaceutical entity dedicated to exploring and advancing novel treatment options for cancer patients. The company’s developmental pipeline featured its proprietary VersAptx bioconjugation platform, alongside several promising drug candidates. Among these was VIP943, an antibody-drug conjugate (ADC) designed to target hematologic malignancies, and enitociclib, a cyclin-dependent kinase-9 inhibitor, both of which had progressed into early-stage clinical trials. Additionally, its portfolio included VIP236, a small molecule drug conjugate for solid tumors, and preclinical ADC asset VIP924. However, following unsuccessful attempts at strategic mergers, including with Oqory, Inc. and QumulusAI, and facing significant financial constraints, Vincerx Pharma has since moved to terminate previous business combination agreements. The company’s board of directors has authorized management to commence wind-down activities, including exploring asset monetization and out-licensing, and is actively seeking stockholder approval for a dissolution and liquidation plan. Vincerx Pharma, Inc. was established in 2019 and maintained its operational base in Palo Alto, California.